Skip to main content
Professor Peptides
Research compound

Ipamorelin + Tesamorelin Blend

Also known as Ipamorelin + Tesamorelin · Tesa/Ipa blend

Same dual-pathway logic as CJC/ipamorelin, but with the FDA-approved GHRH analogue

Last reviewed · Educational reference — not medical advice.

Half-life
Not characterised in published human pharmacokinetic studies
Route
Subcutaneous injection in reported research use
Status
Compounded blend — no studies of the combination
Mechanism
GHRH analogue (tesamorelin) plus ghrelin receptor agonist (ipamorelin): stimulation of GH release through two receptor systems, with ipamorelin additionally reducing somatostatin inhibitory tone. Tesamorelin's distinguishing clinical property is reduction of visceral adipose tissue.
01

Overview

This blend applies the standard GH-axis dual-pathway logic — a GHRH analogue plus a ghrelin receptor agonist — but uses tesamorelin as the GHRH component instead of CJC-1295.

That substitution has a substantive point in its favour. Tesamorelin is a stabilised GHRH analogue that, unlike CJC-1295, has been through formal clinical development, with an approved indication for reducing excess visceral adipose tissue in HIV-associated lipodystrophy. Its effect on visceral fat specifically is the best-established outcome of any GHRH analogue, which is why this pairing is marketed with a visceral fat emphasis rather than a general 'anti-ageing' one.

The blend itself has not been studied. Tesamorelin's evidence comes from its own clinical programme at defined doses in a defined population — not from combination use with a ghrelin receptor agonist in healthy individuals, which is a different question entirely.

See our individual ipamorelin and tesamorelin entries.

Research areasGrowth hormone axis regulationVisceral adipose tissueGHRH analogue pharmacology
02

What the evidence shows

Separated by study type
HumanClinical trials and human studies
No trial of this combination was located. Tesamorelin individually has a clinical development programme and an approved indication for reducing excess visceral adipose tissue in HIV-associated lipodystrophy.
AnimalRodent and other animal models
No studies of the combination located.
In vitroCell and tissue studies
Receptor pharmacology of each component is separately characterised.
03

Key studies & findings

1 study
  1. 1

    No study of the ipamorelin plus tesamorelin combination was located. Tesamorelin's visceral adipose tissue evidence comes from its own clinical programme in HIV-associated lipodystrophy, not from combination use.

    No combination study located

04

Benefits & effects

2 documented

  • Uses the best clinically documented GHRH analogue available

    Verified

  • Dual-pathway GH axis stimulation

    Verified
05

Side effects & safety

2 reported

Safety noteCompounded blend of research compounds for laboratory use only. Premixed blends compound the unknowns of each component and add one of their own: if an adverse effect occurs, the responsible component cannot be identified.

Recorded in the cited literature No safety data for the combination.

  • Elevated GH and IGF-1 carry their own risks including insulin resistance

    Moderateunknown

  • Adverse effects cannot be attributed to a specific component

    unknown
06

Limitations & open questions

This is a fixed-ratio premixed combination, and that carries specific consequences beyond those of its individual components. The components cannot be titrated independently — adjusting one means adjusting all of them. If a reaction occurs, attribution is impossible. And the combination itself has not been studied: evidence for the individual compounds does not transfer to the mixture, because combined pharmacology is not the sum of separate pharmacologies. Blends are a convenience and pricing format, not a validated pharmacological unit. Tesamorelin's clinical evidence was generated at defined doses in a specific population with HIV-associated lipodystrophy. Borrowing that evidence to support combination use in healthy individuals is a substantial extrapolation that the trials do not license.

07

Pharmacology

A mixture rather than a single chemical entity. Tesamorelin is a stabilised GHRH analogue with an approved clinical formulation; ipamorelin is a short-acting selective ghrelin receptor agonist. See the individual entries.

08

Frequently asked questions

Why use tesamorelin instead of CJC-1295?

Tesamorelin has been through formal clinical development and has an approved indication for reducing excess visceral adipose tissue in HIV-associated lipodystrophy. CJC-1295 has not. That makes tesamorelin the better-documented GHRH analogue, though the blend itself remains unstudied.

Does tesamorelin's approval apply to this blend?

No. Its evidence comes from defined doses in people with HIV-associated lipodystrophy. Combination use with a ghrelin receptor agonist in healthy individuals is a different question that has not been tested.